Sonoma Pharmaceuticals (SNOA) risk factors

32 risks, 1 new, 1 dropped, 5 reworded since the prior year. Product recalls, safety or efficacy allegations, mislabeling, and regulatory violations are newly highlighted as threats to sales and reputation.

32 risks. Sonoma Pharmaceuticals relies heavily on international sales, particularly in Mexico and Europe, exposing it to foreign exchange, tariff, and credit risks. The company faces a going concern warning with an accumulated deficit of $197,806,000 as of March 31, 2025. Significant customer concentration exists, with customer B and customer C accounting for 21% and 18% of net revenues.